Skip to content
Screener

Total Equity at other companies

Arvinas logo
ArvinasARVN
$386.8M-41.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.51B+55.4%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$487.28M+81.8%
Septerna, Inc. logo
Septerna, Inc.SEPN
$378.46M+195%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$394.88M+12.8%
Regenxbio logo
RegenxbioRGNX
$71.77M-66.4%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemMay 31,2026November 30,2025
Stockholdersʼ equity:
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2026 and November 30, 2025; no shares issued and outstanding as of May 31, 2026 and November 30, 2025
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2026 and November 30, 2025; 103,701,511 and 101,807,484 shares issued and outstanding as of May 31, 2026 and November 30, 2025, respectively104102
Additional paid-in capital1,582,6031,541,766
Accumulated other comprehensive income (loss)(145)105
Accumulated deficit(1,179,935)(1,003,226)
Total stockholdersʼ equity402,627538,747
Total liabilities and stockholdersʼ equity$535,540$688,135

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s total equity?
Nurix Therapeutics, Inc. (NRIX) reported total equity of $402.63M in Q1 2026.
How has Nurix Therapeutics, Inc.'s total equity changed year-over-year?
Nurix Therapeutics, Inc.'s total equity decreased by 10.0% year-over-year, from $447.6M to $402.63M.
What is the long-term trend for Nurix Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s total equity has grown at a 13.2% compound annual growth rate (CAGR), from $290.27M to $538.75M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Nurix Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude